

**NOTICE OF NEW HAMPSHIRE MEDICAID
DRUG UTILIZATION REVIEW BOARD
PUBLIC HEARING
May 20, 2014**

The New Hampshire Drug Utilization Review (DUR) Board invites you to attend a public hearing at 2:00 p.m., on May 20, 2014 at the Brown Building – Auditorium, 129 Pleasant Street, Concord, NH. A DUR meeting will immediately follow this public hearing.

The purpose of the public hearing is to solicit information and provide an opportunity for the public to present its views regarding the NH Medicaid preferred drug list and pharmacy prior authorization criteria.

The public hearing will begin at 2:00 p.m. and end no later than 3:00 p.m. The DUR meeting will begin at or before 3:00 p.m., upon completion of public comments. The public is invited to present oral comments regarding the preferred drug list and prior authorization criteria for the public hearing. Members of the public shall notify the Department of Health and Human Services (DHHS) at least 48 hours in advance of the public hearing of their intent to comment at the public hearing. Comments will be limited to no longer than five (5) minutes per person and will be limited to the items on the agenda as they relate to the preferred drug list and prior authorization criteria.

Written material may also be submitted by the public for DUR Board consideration if received by DHHS at least 48 hours in advance of the meeting and may not exceed five (5) pages in length.

**DRUG UTILIZATION REVIEW BOARD MEETING
May 20, 2014
Meeting Agenda**

- I. Introductions and Welcome to Board Members
- II. Old Business
 - a. Minutes – 06/18/12 review
- III. New Business
 1. DUR Business Operations
 2. Overview of Drug Utilization Patterns for New Hampshire Medicaid
 - Prospective DUR Reports
 - Utilization Reports
 - Retrospective DUR Reports
 3. Review of New Proposed Preferred Drug List Therapeutic Classes
 - Opiate Dependence Treatment (Pharmacy claims only)
 - Self Injectable Epinephrine
 - Homozygous Familial Hypercholesterolemia
 - Sodium-glucose co-transporter 2 (SGLT2) inhibitor
 - Hepatitis C – Nucleotide Analog Inhibitor
 4. Review of Current Clinical Prior Authorization Criteria with Proposed Changes
 - Hepatitis C
- IV. Adjourn

Further information regarding the agenda items may be obtained after April 29, 2014. Notice of intent to testify at the public hearing, and/or submittal of written comments, should be directed to Kelly Cote, Office of Medicaid Business and Policy, 129 Pleasant Street, Concord, NH, 03301, 1-800-852-3345, ext. 79422 (in state only), (603) 271-9422, or e-mail at: kmcote@dhhs.state.nh.us.